Preclinical Models of Traumatic Brain Injury
Traumatic brain injury (TBI) has been called a silent epidemic. The United States Centers for Disease Control and Prevention reports that over 2.5 million TBIs occurred in the United States in 2010 alone. Pharmacotherapies targeted at mitigating early post - traumatic secondary degenerative pathology such as inflammation, oxidative stress and excitotoxicity, as well as therapies to promote brain plasticity in order to restore function continue to require preclinical testing.
Read More